This Teradyne Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Wall Street analysts changed ratings for top stocks. See full list at Benzinga's analyst ratings page. TER, TX and more.
Read original at benzingaStocks · News reference
Health Catalyst Sees Q3 Sales $55.000M-$56.000M vs $62.159M Est
Health Catalyst (NASDAQ:HCAT) sees Q3 sales of $55.000 million-$56.000 million vs $62.159 million analyst estimate.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 8:09 PM
- Checked
- Aug 6, 2026, 8:09 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Canaccord Genuity Downgrades Health Catalyst to Hold, Lowers Price Target to $1.8
Canaccord Genuity analyst Richard Close downgrades Health Catalyst (NASDAQ:HCAT) from Buy to Hold and lowers the price target from $3 to $1.8.
Read original at benzingaWells Fargo Maintains Equal-Weight on Health Catalyst, Lowers Price Target to $1.5
Wells Fargo analyst Stan Berenshteyn maintains Health Catalyst (NASDAQ:HCAT) with a Equal-Weight and lowers the price target from $1.75 to $1.5.
Read original at benzingaCitigroup Maintains Neutral on Health Catalyst, Lowers Price Target to $2
Citigroup analyst Daniel Grosslight maintains Health Catalyst (NASDAQ:HCAT) with a Neutral and lowers the price target from $2.5 to $2.
Read original at benzinga